- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | Nasus Pharma Targets Q4 Pivotal Study For Intranasal Epinephrine In $2 Billion Market, With Topline Data Expected Q1 2027 | 1 | pulse2.com | ||
| Mi | Nasus Pharma CFO Eyal Rubin to depart in September | 1 | Investing.com | ||
| Mi | Nasus Pharma CFO Eyal Rubin to leave | 2 | Seeking Alpha | ||
| Mi | Nasus Pharma, Ltd.: Nasus Pharma Announces Transition of Chief Financial Officer | 262 | GlobeNewswire (Europe) | TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development... ► Artikel lesen | |
| Mo | Nasus Pharma 1H non-GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
| Mo | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | Nasus Pharma, Ltd.: Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update | 360 | GlobeNewswire (Europe) | Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE... ► Artikel lesen | |
| 28.07. | Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman | 1 | RTTNews | ||
| 28.07. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.07. | Nasus Pharma names Brendan O'Grady as new CEO | 1 | Investing.com | ||
| 28.07. | Nasus Pharma, Ltd.: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth | 250 | GlobeNewswire (Europe) | TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of... ► Artikel lesen | |
| 09.06. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.06. | Nasus Pharma reports positive preclinical data for NS003 | 1 | Investing.com | ||
| 26.05. | Nasus Pharma Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 26.03. | Citizens senkt Kursziel für Nasus Pharma auf 18 US-Dollar | 1 | Investing.com Deutsch | ||
| 26.03. | Citizens cuts Nasus Pharma stock price target to $18 on valuation | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.03. | Nasus Pharma legt positive Phase-2-Daten für Adrenalin-Nasenspray vor | 1 | Investing.com Deutsch | ||
| 25.03. | Nasus Pharma reports Phase 2 results for intranasal epinephrine | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM BIOPHARMA | 2,836 | 0,00 % | Quantum Biopharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Aug. 21, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 63,44 | +0,13 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 4,030 | -0,25 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| OPKO HEALTH | 1,280 | +0,79 % | OPKO Health Secures $125 Million Financing Against Mazdutide Royalties | ||
| OPUS GENETICS | 3,620 | +4,02 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| PROTHENA | 8,074 | -0,27 % | Prothena Corporation plc: Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 3,060 | +0,66 % | NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript | ||
| ORIC PHARMACEUTICALS | 11,780 | -3,05 % | ORIC Pharmaceuticals: ORIC Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA (Darolutamide), Supported by Clinical Collaboration with Bayer | Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,351 | -0,20 % | Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback... ► Artikel lesen | |
| OMNIAB | 4,325 | -0,12 % | Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague | ||
| PROCESSA PHARMACEUTICALS | 2,050 | -1,44 % | Processa Pharmaceuticals: Aktionäre stimmen Erweiterung des Anreizplans zu | ||
| PRF TECHNOLOGIES | 0,997 | 0,00 % | PRF Technologies Ltd.: PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms | TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF", "PRF Technologies" or the "Company") today issued a Letter to Shareholders from Efraim Cohen-Arazi... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 3,920 | 0,00 % | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | -- Executing IND-enabling activities for next-generation PI3Ka pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027... ► Artikel lesen | |
| ANBIO BIOTECHNOLOGY | 6,100 | -4,69 % | Anbio Biotechnology - 6-K, Report of foreign issuer | ||
| PMGC | 6,550 | -1,65 % | PMGC Holdings Inc.: NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight | New Filings Extend EL-22 and EL-32 into Spaceflight-Associated Muscle Atrophy, Broadening NorthStrive's Myostatin and Activin A Intellectual Property Portfolio Across Human Weight-Loss, Space Health... ► Artikel lesen |
Das Unternehmen NASUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.